NIKA NIKA PHARMACEUTICALS, INC
Pharmaceutical Preparations · OTC · SEC CIK 1145604 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-60.7%
TTM EPS YoY—
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE—
ROA-574.9%
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets6,574.0%
Debt / equity—
Current ratio0.02x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.85x
Accruals ratio-85.6%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | — | — | — | — | — | — | — | — |
| SG&A expense | $8,177 | $14,848 | $2,639 | $33,023 | $3,901 | $14,300 | $1,800 | $6,358 |
| Operating income | -$13,023 | -$19,694 | -$13,359 | -$37,089 | -$7,982 | -$18,381 | -$12,945 | -$12,453 |
| Pretax income | -$13,023 | -$19,694 | -$13,359 | -$37,089 | -$7,982 | -$18,381 | -$12,945 | -$12,453 |
| Net income | -$13,023 | -$19,694 | -$13,359 | -$37,089 | -$7,982 | -$18,381 | -$12,945 | -$12,453 |
| EPS (basic) | 0.00 | 0.00 | 0.00 | — | 0.00 | 0.00 | 0.00 | — |
| EPS (diluted) | 0.00 | 0.00 | 0.00 | — | 0.00 | 0.00 | 0.00 | — |
| Weighted avg. shares (diluted) | 1.05B | 1.05B | 1.05B | — | 1.04B | 1.03B | 1.03B | — |
| Balance sheet | ||||||||
| Cash & equivalents | $352 | $2,932 | $1,530 | $1,889 | $6,287 | $15,616 | $19,137 | $2,083 |
| Current assets | $5,309 | $9,942 | $20,637 | $20,996 | $23,625 | $31,607 | $34,988 | $17,934 |
| Total assets | $5,309 | $9,942 | $20,637 | $20,996 | $23,625 | $31,607 | $34,988 | $17,934 |
| Current liabilities | $349,014 | $340,624 | $331,624 | $318,624 | $284,164 | $284,164 | $269,164 | $239,164 |
| Short-term debt | $349,014 | $340,624 | $331,624 | $318,624 | $284,164 | $284,164 | $269,164 | $239,164 |
| Total liabilities | $349,014 | $340,624 | $331,624 | $318,624 | $284,164 | $284,164 | $269,164 | $239,164 |
| Shareholders' equity | -$343,705 | -$330,682 | -$310,988 | -$297,628 | -$260,539 | -$252,557 | -$234,176 | -$221,231 |
| Shares outstanding | 1.05B | 1.05B | 1.05B | 1.05B | 1.04B | 1.03B | 1.03B | 1.05B |
| Cash flow statement | ||||||||
| Operating cash flow | -$10,970 | -$7,598 | -$13,359 | -$38,858 | -$9,329 | -$18,522 | -$12,945 | -$12,452 |
| Financing cash flow | $8,390 | $9,000 | $13,000 | $34,460 | $0 | $15,000 | $30,000 | $29,000 |
Free plan shows the latest 8 periods; Pro shows all 27 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.